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Abstract 
In the human isolated myocardium, acetylcholine (10 -9 to 10 -3 M) elicited a biphasic inotropic effect (a decrease in the 
lower and an increase in the higher concentration range) in atrial and a positive inotropic effect in ventricular trabeculae. 
However, under conditions of raised contractility achieved by exposure to noradrenaline (10 -5 M), only negative inotropic effects 
were observed in both atria and ventricles. Atropine (10 -6 M), but not propranolol (10 -6 M), antagonized both positive and 
negative inotropic effects of acetylcholine, thus showing that the responses were mediated by muscarinic acetylcholine receptors. 
The use of subtype selective muscarinic receptor antagonists (10 -7 to 10 -5 M), pirenzepine (M 1 > M 3 > M2) , AF-DX 116 
(••-({2-[(diethy•amin•)-methy•]-•-piperidy•}acety•)-5•••-dihydr•-6H-pyrid••[2•3-b][••4]benz•diazepine-6-•ne bas ; M 2 > M 1 > M 3) 
and HHSiD (p-fluorohexahydro-siladifenidol hydrochloride; M 3 >_ M 1 >> M 2) revealed that the negative inotropic effect of 
acetylcholine in atrial as well as the positive inotropic effect in ventricular t abeculae were best antagonized by AF-DX 116 and 
not by pirenzepine, suggesting the involvement of the muscarinic M 2 receptor subtype, possibly linked to different second 
messenger systems. On the other hand, the positive inotropic effect of acetylcholine (10 -6 to 10 -3 M) in the atrial tissue, 
observed only in preparation with depressed contractility, was not effectively antagonized by either AF-DX 116 or HHSiD, but 
was significantly reduced by pirenzepine. Furthermore, the selective muscarinic M 1 receptor agonist McN-A-343 (4-(m-chloro- 
phenylcarbamoyloxy)-2-butynyltrimethyl ammonium chloride; 10 -9 to 10 -3 M), which failed to significantly change the baseline 
contractility in either atrial or ventricular t abeculae, produced apositive inotropic effect in atrial preparations when contractility 
had been depressed by prior treatment with acetylcholine (10 -9 to 10 -7 M). This effect of McN-A-343 was effectively 
antagonized by pirenzepine (10 -5 M). These data show that, besides the muscarinic M 2 receptor mediating both negative (atria) 
and positive (ventricle) inotropic effects, muscarinic M 1 receptors, capable of reversing depressed atrial contractility, are present 
in the human heart. 
Keywords: Acetylcholine; Atrium AF-DX 116, human; HHSiD (p-fluorohexahydro-siladifenidol hydrochloride); McN-A-343; 
Muscarinic receptor; Myocardial contractility; Pirenzepine; Ventricle 
I .  Introduction 
It is well known that acetylcholine causes negative 
inotropic and chronotropic effects in the mammalian 
heart, including humans (Brodde et al., 1992; Caulfield, 
1993; B6hm et al., 1994; Landzberg et al., 1994). In 
addition, studies have shown that acetylcholine can 
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elicit a positive inotropic response in isolated cardiac 
tissue of some species (Endoh and Blinks, 1984; Tajima 
et al., 1987; Eglen et al., 1988). In our previous tudy in 
the human isolated myocardium, we reported that 
acetylcholine licited a biphasic response (an initial 
decrease followed by an increase in contractility back 
to baseline values) in the atrial trabeculae, whereas 
only a positive inotropic effect was noticed in the 
ventricular trabeculae (Duet  al., 1994). This latter 
effect was not observed earlier (Jakob et al., 1989; 
Deighton et al., 1990; B6hm et al., 1994). 
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Five muscarinic acetylcholine r ceptor subtype genes 
have been cloned and expressed, but only muscarinic 
M 2 receptors have been detected in the human heart 
(Maeda et al., 1988; Ford et al., 1992; Caulfield, 1993). 
Correspondingly, the responses to muscarinic receptor 
agonists in the cardiac muscle appear to be mediated 
by the activation of well-characterized muscarinic M 2 
receptors, which are coupled to different signal trans- 
duction pathways (Schimerlik, 1989). However, the car- 
diac effects of muscarinic receptor stimulation are not 
yet fully understood and evidence is emerging that, 
besides the muscarinic M 2 receptor, other muscarinic 
receptor subtypes are also expressed in the heart. For 
example, the muscarinic M 1 receptor seems to mediate 
positive inotropic effects in cells isolated from adult 
guinea-pig ventricles (Gallo et al., 1993) as well as the 
increase in automaticity in canine Purkinje fibres (Ro- 
sen et al., 1990). Furthermore, it has been reported 
that low doses of pirenzepine ( < 3 rag) cause bradycar- 
dia that coincides with the blockade of muscarinic M1 
receptors in humans (Pitschner and Wellstein, 1988). 
Thus, it is suggested that although the predominant 
population of muscarinic receptors at postsynaptic sites 
in the heart is of the M 2 subtype, a small population of 
M 1 subtype is also present (Watson et al., 1983; Evans 
et al., 1985). 
The purpose of the present study was to charac- 
terize the receptors involved in the observed inotropic 
effects of acetylcholine in the human cardiac tissue 
(Duet  al., 1994) by using relatively selective antago- 
nists at the muscarinic M1, M 2 or M 3 receptors (Doods 
et al., 1987) as well as a selective agonist at the mus- 
carinic M 1 receptor. A part of this investigation has 
been presented at the last winter meeting of the British 
Pharmacological Society (Du et al., 1995). 
2. Material and methods 
2.1. Preparations 
Right atrial and left ventricular trabeculae were 
obtained from 61 heart beating organ donors (43 males, 
18 females aged 2-55 years), who died of non-cardiac 
disorders (36 cerebrovascular ccident, 20 polytrauma, 
5 hypoxia) less than 24 h before the tissue was brought 
to the laboratory. The hearts were kindly provided by 
the Rotterdam Heart Valve Bank (Bio Implant Ser- 
vices Foundation/Eurotransplant Foundation) after 
removal of the aortic and pulmonary valves for homo- 
graft valve implantation. The hearts were stored at 
0-4°C in a sterile organ protecting solution (UW, Eu- 
rocollins, or HTK-Brettschneider, see Ploeg et al., 1992) 
immediately following circulatory arrest. After exci- 
sion, tissue samples were placed in ice-chilled oxy- 
genated Krebs buffer (composition in Mm: NaC1 118, 
KCI 4.7, CaC12 2.5, MgSO 4 1.2, NaHCO 3 25, KHPO 4 
1.2 and glucose 8.3) and atrial and ventricular trabecu- 
lae (< 1 mm thickness) were carefully dissected free. 
The trabeculae were mounted in organ baths contain- 
ing Krebs buffer (37°C, gassed with 95% 0 2 and 5% 
CO 2) and paced at 1 Hz using electrical field stimula- 
tion (3 ms, voltage 20% above threshold). The devel- 
oped tension was recorded using isometric Harvard 
transducers and Goerz flatbed recorders (Schoemaker 
et al., 1993; Duet  al., 1994). Based on preliminary 
experiments, the chosen optimal resting load, yielding 
the highest developed tension, was 750 mg and 1950 
mg for atrial and ventricular trabeculae, respectively. 
2. 2. Experimental protocol 
After stabilization, the resting tension and baseline 
contractile force were measured. A concentration-re- 
sponse curve for noradrenaline was obtained to check 
the viability of the tissues (Schoemaker et al., 1993; Du 
et al., 1994). Tissues with less than 25 mg response to 
10 -5 M noradrenaline were excluded from further 
analysis. 
After washing (6 times) and stabilization, 10 -6 M 
physostigmine was added to the Krebs buffer in experi- 
ments involving acetylcholine to prevent its rapid 
degradation by cholinesterase (see Chatonnet and 
Lockridge, 1989). One cumulative concentration-re- 
sponse curve for acetylcholine (10 -9 to 10 -3 M) was 
constructed in each atrial and ventricular preparation, 
in the absence (control) or after 30 min incubation with 
one of the following antagonists: propranolol (10 -6 M, 
non-selective /3-adrenoceptor antagonist), atropine 
(10-6 M, non-selective muscarinic receptor antagonist), 
pirenzepine (10 -7, 10 -6 or 10 -5 M, muscarinic M 1 
receptor antagonist, Hammer et al., 1980), AF-DX 116 
(10 -7, 10 -6 or 10 -5 M, muscarinic M e receptor antag- 
onist, Giachetti et al., 1986) and HHSiD (10 -6 or 10 -5 
M, muscarinic M 3 receptor antagonist, Lambrecht et 
al., 1989). In addition, the effects of acetylcholine on 
trabeculae pre-stimulated with noradrenaline (10 -5 M) 
were investigated either in the absence or presence of 
10 -6 M atropine. 
Since not all effects of acetylcholine could be fully 
explained after the use of antagonists, we also investi- 
gated the effects of a muscarinic M 1 receptor agonist, 
McN-A-343. One cumulative concentration-response 
curve for McN-A-343 (10 -9 to 10 -3 M) was obtained 
in each atrial and ventricular preparation. In addition, 
in the atrial tissue, cumulative concentration-response 
curves for McN-A-343 (10 -9 to 10 -3 M) were also 
constructed following a maximal negative inotropic ef- 
fect induced by acetylcholine (10 -9 tO >_ 10 -6 M), in 
the absence or presence of pirenzepine (10 -5 M). 
There was no apparent difference in the responses 
to noradrenaline or acetylcholine observed in trabecu- 
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lae obtained from subjects of different age or dying 
from different causes. This is also true for a number of 
other subtances, including 5-hydroxytryptamine and 
histamine (Schoemaker et al., 1993; Du et al., 
1993,1994). 
2.3. Data presentation and analysis 
Data are presented as means + S.E.M. Baseline val- 
ues for atrial and ventricular tissue were compared 
using an unpaired t-test. The effects of acetylcholine 
and McN-A-343 in the absence or presence of various 
antagonists were analyzed using an analysis of variance 
for repeated measurements. Differences were regarded 
statistically significant, if P < 0.05. Since the negative 
inotropic response in atrial and the positive inotropic 
response in ventricular tissues reached their maximum, 
the curves were fitted to a four-parameter logistic 
function (De Lean et al., 1978) to calculate, where 
applicable, apparent pD 2 values (negative logarithm of 
the molar concentration eliciting half-maximal effect). 
Apparent pK B values were derived from pD 2 values, 
using the following equation: pK B =-Log[B]  + 
Log{([Az]/[At]) -1},  where [B] is the molar concen- 
tration of antagonists and [A I ]  and [A2]  represent 
molar concentrations of agonists eliciting half-maximal 
effect in the absence and presence of antagonists, 
respectively. 
2.4. Chemicals used 
The chemicals used in the present study were: 
acetylcholine chloride (Ciba, Breda, Netherlands), AF- 
DX 116 (ll-({2-[(diethylamino)-methyl]-l-piperidyl} 
acetyl)-5,11-dihydro-6 H pyridol[ 2,3-b ][1,4]benzodi- 
azepine-6-one base; Thomae, Biberach/Riss, Germa- 
ny), atropine sulphate (Centrafarm, Etten-Leur, Neth- 
erlands), HHSiD (p-fluorohexahydro-siladifenidol hy- 
drochloride; Research Biochemicals International, 
Natick, MA, USA), McN-A-343 (4-(m-chlorophenyl- 
carbamoyloxy)-2-butynyltrimethylammonium chloride; 
McNiel, Fort Washington, PA, USA), noradrenaline 
bitartrate (Sigma, St. Louis, MO, USA), physostigmine 
salicylate (Sandoz, Basel, Switzerland), pirenzepine 
base (Thomae, Biberach/Riss, Germany), propranolol 
hydrochloride (Imperial Chemical Industries, Maccles- 
field, UK). 
3. Results 
3.1. Viability of the tissues 
The baseline contractile force was significantly lower 
in the atrial (97 + 13 mg, n = 57) than in ventricular 
(236 + 30 mg, n = 54) tissue. In both tissues, nor- 
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Fig. 1. Cumulative concentration-response curves of acetylcholine 
(Ach) on the baseline force of contraction, obtained in the atrial (left 
panel) and ventricular (right panel) trabeculae in the absence (O, 
n = 5 and 6, respectively) or presence of 10 -6 M atropine (A,  n = 6 
each) or propranolol (11, n = 7 and 6, respectively). 
adrenaline (10 -8 M to 10 -5 M) increased contractile 
force in a concentration-dependent manner. After ex- 
posure to 10 -5 M noradrenaline, the force of contrac- 
tion went up to 381 + 35 mg (n = 57) and 627 + 65 mg 
(n = 54) in the atrial and ventricular trabeculae, re- 
spectively. 
3.2. Inotropic responses to acetylcholine in atrial and 
uentricular trabeculae 
Effect on the baseline contractility 
The effect of acetylcholine on the baseline atrial 
and ventricular contractility as well as the influence of 
atropine and propranolol are shown in Fig. 1. In right 
atrial trabeculae, acetylcholine xhibited a biphasic 
contractile response consisting of an initial decrease 
followed by an increase. At low concentrations (10 -9 
to 10 -7 M), acetylcholine clearly decreased the base- 
line contractile force (maximum decrease from base- 
line values: 67 + 13% at 10 -7 M), but with higher 
concentrations the contractile force started to increase 
towards baseline values (0 _+ 23% change from baseline 
values at ]0  -3  U) .  If after exposure to ]0  -7  M acetyl- 
choline higher concentrations were not used, the con- 
tractile force remained epressed without coming back 
towards baseline values. However, when 10 -4 M 
acetylcholine was administrated without the preceding 
part of the concentration-response curve, no positive 
inotropic effect was observed (data not shown). In 
contrast o atria, acetylcholine caused only a positive 
inotropic effect in left ventricular trabeculae. The max- 
imum increase in contractile force (53 _+ 17% from 
baseline values) was observed at 10 -3 M. 
Atrop ine  ( ]0  -6  M)  effectively antagonized both the 
negative and positive inotropic effects of acetylcholine 
in atrial as well as the positive inotropic effect in 
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Fig. 2. Cumulative concentration-response curves of acetylcholine 
(Ach) on force of contraction after pre-stimulation with noradrena- 
line (NA; 10 -5 M), obtained in the atrial (left panel) and ventricular 
(right panel) trabeculae in the absence (O, n = 7 and 6, respectively) 
or presence of atropine (10 -6 M; A, n = 7 and 5, respectively). 
ventr icular trabeculae. Since in the presence of at- 
ropine a complete concentrat ion-response curve to 
acetylcholine could not be constructed, pD 2 values of 
acetylcholine were not calculated. However,  from Fig. 
1 it can be seen that atropine shifted the concentra- 
t ion-response curve to the right by more than 3 and 4 
log units in atrial and ventr icular trabeculae, respec- 
tively. Propranolol  (10 -6 M) did not modify the re- 
sponses to acetylcholine. 
Effect on noradrenaline-stimulated contractility 
In the presence of  noradrenal ine (10 -5 M), acetyl- 
chol ine produced only a negative inotropic effect in 
both atrial and ventr icular trabeculae (Fig. 2). The 
reduct ion of the contracti le force by 10 -3 M acetyl- 
chol ine was from 504 + 141 to 43 + 6 mg (86 _ 4%) in 
atrial trabeculae (n = 7) and from 463 + 93 to 288 + 59 
mg (39 + 5%) in ventr icular trabeculae (n = 6). The 
pD 2 value for acetylcholine was 7.0 + 0.6 (n = 5) and 
6.8 + 0.9 (n = 6) in the atrial and ventr icular tissues, 
respectively. 
Atrop ine shifted the concentrat ion-response curve 
for acetylcholine to the right in both atrial and ventric- 
ular tissue following pre-st imulat ion with 10 -5 M nor- 
adrenal ine (Fig. 2). The pD 2 values for acetylcholine 
were decreased in both atrial (4.5 + 0.1; n = 7) and 
ventr icular (4.8 + 0.3; n = 5) trabeculae. 
3.3. Effect of the muscarinic receptor antagonists on 
acetylcholine-induced inotropic responses 
Right atrium 
Fig. 3 presents concentrat ion-response curves to 
acetylcholine in atrial trabeculae in the absence (con- 
trol) or presence of  the three relatively selective mus- 
carinic receptor  antagonists, whereas the relevant pa- 
rameters of these curves are summarized in Table 1. 
The muscarinic M t receptor  antagonist pirenzepine 
(10 -7, 10 -6 or 10 -5 M) did not significantly change the 
negative inotropic effect of acetylcholine (10 -9 to 10 -6 
M), whereas the positive inotropic effect of acetyl- 
chol ine (10 -6 to 10 -3 M) was significantly reduced by 
pirenzepine at the highest concentrat ion (10 -5 M; pK  B 
could not be calculated). The muscarinic M e receptor  
antagonist AF -DX 116 did not significantly affect the 
negative inotropic effect of  acetylcholine at 10 -7 M, 
but 10 -6 M AF-DX 116 produced a parallel shift to 
the right of the acetylcholine curve (apparent PKB: 
6.7 + 0.4; n = 8) and 10 -5 M AF-DX 116 completely 
abolished the negative inotropic effect. AF -DX 116 
either did not affect (10 -7 and 10 -6 M) or even 
seemed to increase (10 -5 M) the positive inotropic 
Table 1 
Maximum negative (with apparent pD 2) and positive inotropic effects in atrial and maximum positive inotropic effect (with apparent pD 2) in 
ventricular trabeculae induced by acetylcholine 
Antagonist Iz M Atrium Ventricle 
n Negative a pD 2 Positive b n Positive c pD 2 
Control 16 47 + 12 6.8 5:0.2 78 5:11 14 33 5:6 5.6 + 0.4 
Pirenzepine 0.1 6 73 ± 10 7.1 5:0.2 29 5:15 ~ 5 37 5:5 6.3 5:0.2 
Pirenzepine 1 8 61 + 7 6.4 + 0.2 37 5:11 d 4 56 5:16 5.1 _+ 0.6 
Pirenzepine 10 6 58 5:6 6.3 5:0.2 4 5:3 d 7 50 5:20 4.7 + 1.8 
Control 16 66 + 5 6.8 + 0.2 68 ± 12 16 46 5:13 5.8 + 0.2 
AF-DX 116 0.1 6 67 5:11 6.6 + 0.1 50 _+ 23 6 38 _+ 9 6.1 + 0.1 
AF-DX 116 1 8 57 + 20 5.9 5:0.2 d 47 + 37 6 26 + 11 4.8 5:0.6 
AF-DX 116 10 6 d,e d,~ 111 + 51 7 29 5:12 3.9 5:0.1 d 
Control 10 70 + 7 7.1 ± 0.2 75 + 30 10 36 + 6 6.2 + 0.3 
HHSiD 1 6 69 5:6 6.8 + 0.1 51 + 31 6 44 + 12 6.0 + 0.2 
HHSiD 10 6 31 _+ 28 d 6.4 + 0.4 106 + 57 5 32 + 10 5.3 + 0.4 
a Percent change from baseline values by acetylcholine (10 -6  M or 10 -5 M in the presence of the two highest concentrations of pirenzepine); 
b percent change by 10 -3  M acetylcholine, calculated as the difference from the maximal negative ffect (pD 2 not calculable); c percent change 
from baseline values by acetylcholine (10 -4  M or 10 -3 M); d significantly different from values in control experiments run in parallel; e only 
positive inotropic response. 
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Fig. 3. Cumulative concentration-response curves of acetylcholine 
(Ach) on baseline force of contraction in the atrial trabeculae in the 
absence or presence of antagonists. Upper left panel: acetylcholine 
alone (n = 16) or in the presence of pirenzepine (10 -7, 10 -6 and 
10 -5 M; n = 6, 8 and 6, respectively). Upper right panel: acetyl- 
choline alone (n = 16) or in the presence of AF-DX 116 10 -7, 10 -6 
and 10 -5 M; n = 6, 8 and 6, respectively). Lower left panel: acetyl- 
choline alone (n = 10) or in the presence of HHSiD (10 -6 and 10 -5 
M; n = 6 each). 
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Fig. 4. Cumulative concentration-response curves of acetylcholine 
(Ach) on baseline force of contraction in the ventricular trabeculae 
in the absence or presence of antagonists. Upper left panel: acetyl- 
choline alone (n = 14) or in the presence of pirenzepine (10 -7, 10 -6 
and 10 -5 M; n= 5, 4 and 7, respectively). Upper right panel: 
acetylcholine alone (n = 16) or in the presence of AF-DX 116 10 -7, 
10 -6 and 10 -5 M; n = 6, 6 and 7, respectively). Lower left panel: 
acetylcholine alone (n = 10) or in the presence of HHSiD (10 -6 and 
10 -5 M; n = 6 and 5, respectively). 
component of the effects of acetylcholine. The prefer- 
ential muscarinic M 3 receptor antagonist HHSiD (10 -6 
M) failed to modify the effects of acetylcholine, but its 
higher concentration (10 -5 M) reduced the negative 
inotropic component (apparent pKB: 6.0 -t- 0.6; n = 6), 
without affecting the positive inotropic component. 
Left ventricle 
The effects of muscarinic receptor antagonists on 
acetylcholine-induced positive inotropic effects in ven- 
tricular trabeculae are shown in Fig. 4 and Table 1. 
Pirenzepine did not efficiently antagonize the re- 
sponses to acetylcholine; only at 10 -5 M pirenzepine, 
the curve for the acetylcholine seemed to be slightly 
shifted to the right (apparent pKB: 5.7 + 0.5; n = 6). 
On the other hand, AF-DX 116 (10 -6 and 10 -5 M) 
caused a concentration-dependent antagonism of the 
responses to acetylcholine (apparent pKB: 6.7-1-0.6 
and 6.2 _+ 0.3, respectively; n = 6 each). HHSiD failed 
to modify the responses to acetylcholine. 
3.4. Effects of MeN-A-343 
Baseline contractility 
The effects of MeN-A-343 (10 -9 to 10 -3 M), a 
relatively selective muscarinic M 1 receptor agonist, on 
the baseline contractility in the atrial and ventricular 
trabeculae are presented in Fig. 5. MeN-A-343 failed 
to significantly alter the force of contraction in either 
tissue; the values before and after MeN-A-343 (10 -3 
M) were 230 + 51 and 208 + 56 mg in atrial trabeculae 
and 348 + 139 and 358 + 130 mg in ventricular trabecu- 
lae. 
Acetylcholine-induced depressed contractility in atrial 
trabeculae 
Fig. 6 presents examples of original tracings howing 
the effects of acetylcholine and MeN-A-343 in atrial 
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Fig. 5. Cumulative concentration-response curves of McN-A-343 on 
baseline force of contraction, obtained in atrial (e) and ventricular 
( • ) trabeculae (n = 6 each). 
124 X.Y. Du et al. / European Journal of Pharmacology 284 (1995) 119-127 
trabeculae. Acetylcholine (]0 -7 M) produced a sus- 
tained negative inotropic effect (panel A), which was 
reversed by higher concentrations of acetylcholine (> 
10 -6 M; panel B) as well as by McN-A-343 (> 10 8 M; 
panel C). Pre-treatment of the atrial trabeculae with 
pirenzepine (10 -5 M) antagonized the positive in- 
otropic effect of McN-A-343 (panel D). 
The mean data obtained in atrial trabeculae with 
McN-A-343 in the absence or presence of 10 -5 M 
pirenzepine (after maximum negative inotropic effect 
was reached by low concentrations of acetylcholine) 
are presented in Fig. 7. Acetylcholine decreased the 
baseline contractile force from 868 -t- 169 mg to 140 _+ 
63 mg ( -84_+ 5%) at 10 7 M (n = 5). McN-A-343 
(10 -9 to 10 -3 M) increased the contractile force back 
to baseline values (902 _+ 170 mg at 10 -3 M; n = 5) in a 
concentration-dependent way (PD2:6.75 _+ 0.42). Al- 
though pirenzepine (10 -5 M) slightly shifted the 
acetylcholine curve to the right, it strongly antagonized 
the McN-A-343-induced positive inotropic effect. In 
the presence of pirenzepine, the force of contraction 
was not changed by McN-A-343 (10 -9 to 10 -4 M). 
Only at 10 -3 M, McN-A-343 increased the contractility 
from 67 + 17 to 285 + 42 mg, close to baseline values 
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Fig. 7. Cumulat ive concentration-response curves o f  McN-A-343 on 
the force of  contraction in atria] trabeculae after depression of  
contract i l i ty by acety]choline (Ach; ]0 -9 to 10-7 or  10 6 M),  ob- 
tained in the absence (O;  n = 5) or  presence (e; n = 4) o f  piren- 
zepine ( ]0  -5 M).  
(380 _+ 110 mg) (n = 4); the pD 2 value of McN-A-343 
based on the last response was 3.56 + 0.06. The appar- 
ent pK B value of pirenzepine against McN-A-343 was 
found to be 8.57 _+ 0.33 (n = 4). 
A 
9 8 7 
- Log  [Ach]  M 
9 8 7 6 5 4 3 
- Log  [Ach]  M 
D 
9 8 7 6 5 4 3 
-Log [Ach] M 
-Log [McN-A-343]  M 
400 mg 
9 8 7 6 • • • • • • • 
9 8 7 6 5 4 3 
- Log  [Ach]  M 
-Log [McN-A-343] M 
Fig. 6. Recordings of force of contraction i four right atrial trabecu- 
lae showing the effects of acetylcholine (Ach) in different concentra- 
tions. Note that the negative inotropic effect of acetylcholine (10 -7 
M), which was maintained for several min (panel A), was reversed by 
higher concentrations of acetylcholine (panel B) and McN-A-343 
(panel C). The reversal of the negative inotropic effect of acetyl- 
choline by McN-A-343 was not observed in atrial trabeculae pre- 
treated with pirenzepine (10 -5 M) (panel D). 
4. Discussion 
4.1. Involvement of the muscarinic receptors in acetyl- 
choline-induced responses 
The results from the present and previous (Duet  
al., 1994) studies show that in the human isolated 
myocardium acetylcholine elicits complex inotropic ef- 
fects, consisting of a biphasic response (decrease fol- 
lowed by increase at high concentrations) in the atrial 
baseline contractility and only an increase in the ven- 
tricular baseline contractility. However, in conformity 
with previous observations (Jakob et al., 1989; Deighton 
et al., 1990; B6hm et al., 1994) in the isoprenaline-aug- 
mented human isolated myocardium, acetylcholine de- 
creased contractility in both atrial and ventricular 
preparations after prior exposure to noradrenaline. 
The negative inotropic effect of muscarinic holinergic 
agents (antagonized by atropine) is well known, but 
their positive inotropic action, though reported in some 
animal species (rat atria, Imai and Ohta, 1982; guinea- 
pig papillary muscles, Korth and Kiihlkamp, 1987; 
guinea-pig atria, Eglen et al., 1988; chick ventricles, 
Tsuji et al., 1987), has not been reported in humans 
(see Jakob et al., 1989; Deighton et al., 1990; B6hm et 
al., 1994). The reasons for this discrepancy are not 
entirely clear. However, in contrast o our investiga- 
tions performed in non-diseased hearts and with 
acetylcholine in ventricular trabeculae, previous au- 
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thors (Jakob et al., 1989; Deighton et al., 1990; B6hm 
et al., 1994) studied the effects of carbachol on papil- 
lary muscles obtained from hearts removed from pa- 
tients undergoing heart transplantation surgery. 
The precise receptor mechanisms involved in the 
positive inotropic effects of muscarinic cholinergic 
agents are not well understood. In the rat atria (Imai 
and Ohta, 1982), guinea-pig papillary muscle (Korth 
and Kiihlkamp, 1987) and chick ventricles (Tsuji et al., 
1987), the positive inotropic effect was antagonized by 
atropine and, in the last two tissues, it was also shown 
that the effect, being unaffected by prior reserpiniza- 
tion (Korth and Kiihlkamp, 1987) or propranolol (Tsuji 
et al., 1987), was independent of endogenous catechol- 
amines. In accordance with these observations, we also 
found that atropine not only blocked the negative 
inotropic effect in the atria, but also the positive in- 
otropic responses in both atria and ventricles; these 
responses remained unaltered after exposure to pro- 
pranolol. Thus, the results how that both the negative 
and positive inotropic effects of acetylcholine in the 
human isolated myocardium are mediated by mus- 
carinic receptors. 
4.2. Subtypes of muscarinic receptors involved in acetyl- 
choline responses 
Although, at present, highly selective antagonists at
muscarinic receptors are not available, a combination 
of relatively selective antagonists can be employed to 
characterize the muscarinic receptor subtypes. In the 
present investigation, we used three such antagonists 
having different selectivity profiles, namely pirenzepine 
(M l>M 3>M2), AF-DX 116 (M 2>M I>M 3) and 
HHSiD (M 3 >__ M 1 >> M 2) (Doods et al., 1994). How- 
ever, it should be pointed out that the affinity values of 
these relatively selective antagonists obtained in the 
present experiments in the human myocardium are 
further prejudiced by the complex nature of acetyl- 
choline responses. 
Involvement of  the muscarinic M 2 receptor subtype 
The present study showed that AF-DX 116 most 
effectively antagonized the atrial negative inotropic 
(Fig. 3) and ventricular positive inotropic (Fig. 4) ef- 
fects of acetylcholine; the concentration-response 
curves were clearly shifted to the right. The calculated 
apparent pK B values of AF-DX 116 in the atria (6.7 +_ 
0.4) and ventricles (6.7 _+ 0.6) against he negative and 
positive inotropic responses, respectively, to acetyl- 
choline reasonably match with its pK i values (7.14 _+ 
0.06 and 7.18 _+ 0.06, respectively) in the two tissues for 
the displacement of [3H]N-methyl scopolamine in 
guinea-pig membranes (Michel and Whiting, 1987). 
Thus, it appears that the muscarinic M 2 receptor sub- 
type mediates both the negative (in atria) and positive 
(in ventricles) inotropic responses. This conclusion is in 
agreement with the demonstration of the muscarinic 
M 2 receptor mRNA and protein in the human heart 
(Maeda et al., 1988; Caulfield, 1993). Moreover, it is 
now well established that muscarinic M 2 receptors are 
coupled to three signal transduction pathways (Schi- 
merlik, 1989): (i) inhibition of adenylyl cyclase to re- 
duce cAMP (Fleming et al., 1987), (ii) opening of 
potassium channels (Ray and MaCleod, 1993), and (iii) 
hydrolysis of phosphatidylinositol. The first two may 
contribute to the negative inotropic response associ- 
ated with muscarinic receptor stimulation (Hanf et al., 
1993), while the third may induce positive inotropic 
responses (Mizushima et al., 1987; Kohl et al., 1990). 
Although the exact molecular processes are unclear, it 
is believed that the two opposite functional responses 
are mediated via muscarinic M 2 receptors coupled to 
different G-proteins and occurring in different affinity 
states: a high affinity state associated with inhibition of 
adenylyl cyclase and a low affinity state associated with 
the phosphatidylinositol breakdown (Brown and Brown, 
1984). 
A recent study comparing muscarinic K ÷ channels 
in the human atrium and ventricle (Koumi and Wasser- 
strom, 1994) showed that the acetylcholine-induced K ÷ 
current in whole cell preparations from the two tissues 
exhibited essentially similar characteristics, except with 
regard to the channel density. Acetylcholine-induced 
K ÷ current in atria was approximately 2-3 times higher 
than that in ventricles. Another study on the compari- 
son of coupling of muscarinic receptors in guinea-pig 
atrial and ventricular myocardium showed that atrial 
and ventricular eceptors were similar, but receptor 
coupling to cyclase inhibition or phosphatidylinositol 
hydrolysis was distinguishable (Woodcock et al., 1987). 
Thus, it is possible that all three pathways operate to 
mediate the observed tissue responses, but their impor- 
tance may vary in different issues and/or conditions. 
Based on the effect of acetylcholine on the baseline 
contractility (without prior stimulation with, for exam- 
ple, noradrenaline), it would appear that the coupling 
of the rnuscarinic M 2 receptors to adenylyl cyclase 
(negatively) and K ÷ channels may be more important 
in the atrial tissue, whereas in the ventricular tissue the 
muscarinic M 2 receptors probably couple prefer- 
entially to phosphatidylinositol hydrolysis. However, it 
is possible that the coupling can alter in different 
conditions. Indeed, it is interesting to recall that in the 
human ventricular myocardium a concentration-depen- 
dent negative inotropic effect was seen after pre-stimu- 
lation with sympathomimetic agents (Jakob et al., 1989; 
Landzberg et al., 1994; present results). 
Involvement of the muscarinic M 1 receptor subtype 
Experiments with AF-DX 116 and HHSiD in atrial 
tissue showed that the positive inotropic effect of 
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acetylcholine, observed with high concentrations and 
only when the atrial contractility had been depressed, 
was not attenuated and seemed to be potentiated by 
these compounds, apparently due to the elimination of 
the negative inotropic effect. On the other hand, piren- 
zepine seemed to attenuate this response, thereby ac- 
centuating the preceding negative inotropic effect (Fig. 
3). It therefore appears that the acetylcholine-induced 
increase in depressed contractility is mediated by the 
muscarinic M 1 receptor subtype rather than the M 2 or 
M 3 subtype. Although HHSiD has been reported to be 
a more potent antagonist against M 1 than M 2 recep- 
tors (see Doods et al., 1994), this apparently does not 
seem to hold true for the human heart, where this 
compound blocked M 2 receptor mediated responses 
(negative inotropism in atria and positive inotropism in 
ventricles) more effectively. 
The conclusion that the muscarinic M 1 receptor 
subtype mediates acetylcholine-induced increases in 
atrial contractility is further substantiated by the re- 
suits obtained with McN-A-343, which in the radioli- 
gand binding assays has similar affinities for the mus- 
carinic M 1 and M 2 receptor subtypes, but in functional 
assays, probably due to differences in intrinsic efficacy 
and/or  tissue receptor reserve, shows selectivity for 
the muscarinic M 1 receptor subtype (Eglen et al., 1987). 
Indeed, McN-A-343 failed to decrease atrial or in- 
crease ventricular contractility (Fig. 5), thus ruling out 
the activation of muscarinic M 2 receptor subtype in 
the human heart. This compound, however, mimicked 
acetylcholine (higher concentrations) in increasing 
atrial contractility, once this had been depressed by 
prior administration of low concentrations of acetyl- 
choline (Fig. 6). The reversal of the negative inotropic 
effect of acetylcholine by McN-A-343 cannot be due to 
a blockade of muscarinic M 2 receptors, since the effect 
of McN-A-343 was antagonized by pirenzepine. The 
apparent pK B value of pirenzepine against McN-A-343 
(8.57 + 0.33) was similar to the binding affinity of the 
drug at the human cloned muscarinic M t receptor 
(PKi: 8.20 + 0.13; Dorje et al., 1991), thus confirming 
the involvement of muscarinic M 1 receptor subtype. 
Additional evidence for functional atrial muscarinic M 1 
receptors comes from studies of Pitschner and Well- 
stein (1988), who observed that low doses (< 3 mg) of 
pirenzepine decrease heart rate in human subjects. 
Similarly, the bradycardia caused by low doses of at- 
ropine in humans may also be related to blockade of 
muscarinic M 1 receptors (Wellstein and Pitschner, 
1988; present results), rather than central vagal stimu- 
lation (Weiner, 1990). 
Kellar et al. (1985) examined the binding of 
[3H]acetylcholine and suggested that most of the mus- 
carinic M E sites had a high affinity for acetylcholine, 
whereas the majority of muscarinic M l sites had a low 
affinity for acetylcholine. This is in agreement with our 
observations that the positive inotropic response in the 
atrial trabeculae was obtained with high concentrations 
of acetylcholine (10 -4 or 10 -3 M). It is possible that 
the muscarinic M 1 receptors mediating increases in 
atrial contractility are coupled to phosphatidylinositol 
hydrolysis (Gallo et al., 1993; Wess, 1993). 
In conclusion, the present investigation in the hu- 
man isolated myocardium showed that: (i) in addition 
to the generally accepted negative inotropic effect, 
acetylcholine also causes positive inotropic effects at 
similar concentrations in human ventricular trabeculae 
and these negative and positive inotropic responses are 
mediated by the muscarinic M 2 receptor subtype, pos- 
sibly having preferential coupling to adenylyl cyclase 
(negatively) and K ÷ channels in atria, and to phospho- 
inositol breakdown in ventricles, (ii) in trabeculae pre- 
stimulated with noradrenaline, acetylcholine licited 
negative inotropic responses in both atrial and ventric- 
ular trabeculae, suggesting that the preferential cou- 
pling in the ventricles can be altered, and (iii) when 
atrial contractility has already been depressed, high 
concentrations of acetylcholine as well as McN-A-343 
can increase the atrial contractility back towards base- 
line values via the muscarinic M 1 receptor subtype. 
The physiological relevance of the atrial muscarinic M 1 
receptor is not yet clear. 
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